FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980491929> ?p ?o ?g. }

• W2980491929 endingPage "656" @default.
• W2980491929 startingPage "647" @default.
• W2980491929 abstract "ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, European Union, and Japan for all the indications of trastuzumab, based on the totality of evidence (TOE) gathered by the systematic step-wise accumulation of comparative analytical, preclinical, and clinical (pharmacokinetics [PK], efficacy, safety and immunogenicity) data for ABP 980 and trastuzumab reference product (RP). As a key first step of the ABP 980 biosimilar program, comprehensive analytical characterization of critical quality attributes established that ABP 980 is structurally and functionally similar to trastuzumab RP. Complementing these data, results of non-clinical pharmacology, toxicology, and toxicokinetic studies supported similarity between ABP 980 and trastuzumab RP. A randomized study in healthy subjects demonstrated clinical PK equivalence of ABP 980 relative to trastuzumab RP in these subjects. In the final clinical evaluation step, a randomized comparative study (LILAC) confirmed the lack of clinically meaningful differences between ABP 980 and trastuzumab RP in efficacy, safety, and immunogenicity in women with HER2-positive EBC in the neoadjuvant–adjuvant setting. Neoadjuvant EBC represented a sensitive homogenous population for biosimilar demonstrations, and the primary endpoint of pathologic complete response served as a sensitive surrogate endpoint. An important aspect of the LILAC study design is that it is the only study that evaluated the effect of switching from the trastuzumab RP to a trastuzumab biosimilar during the adjuvant phase. No new or unexpected safety signals emerged in the clinical evaluations, with the safety profile of ABP 980 consistent with that previously described for trastuzumab. Overall, the TOE data generated for ABP 980 support the conclusion that it is highly similar to trastuzumab RP, thus providing the scientific justification for extrapolation to all the approved indications of trastuzumab." @default.
• W2980491929 created "2019-10-25" @default.
• W2980491929 creator A5007683245 @default.
• W2980491929 creator A5014416915 @default.
• W2980491929 creator A5027594065 @default.
• W2980491929 creator A5028259807 @default.
• W2980491929 creator A5040735233 @default.
• W2980491929 creator A5053376791 @default.
• W2980491929 creator A5068059897 @default.
• W2980491929 creator A5075849177 @default.
• W2980491929 date "2019-10-16" @default.
• W2980491929 modified "2023-10-01" @default.
• W2980491929 title "Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab" @default.
• W2980491929 cites W1970215590 @default.
• W2980491929 cites W1987326983 @default.
• W2980491929 cites W2044998483 @default.
• W2980491929 cites W2073385822 @default.
• W2980491929 cites W2075894019 @default.
• W2980491929 cites W2100014422 @default.
• W2980491929 cites W2131270246 @default.
• W2980491929 cites W2167121370 @default.
• W2980491929 cites W2169281409 @default.
• W2980491929 cites W2296444677 @default.
• W2980491929 cites W2345015867 @default.
• W2980491929 cites W2399418399 @default.
• W2980491929 cites W2509046259 @default.
• W2980491929 cites W2560234483 @default.
• W2980491929 cites W2603882179 @default.
• W2980491929 cites W2608742892 @default.
• W2980491929 cites W2620735862 @default.
• W2980491929 cites W2766756881 @default.
• W2980491929 cites W2785217251 @default.
• W2980491929 cites W2806386505 @default.
• W2980491929 cites W2820616462 @default.
• W2980491929 cites W2897626749 @default.
• W2980491929 cites W2904249805 @default.
• W2980491929 cites W2911850844 @default.
• W2980491929 cites W2939055585 @default.
• W2980491929 cites W2984412140 @default.
• W2980491929 doi "https://doi.org/10.1007/s11523-019-00675-z" @default.
• W2980491929 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6875516" @default.
• W2980491929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31620980" @default.
• W2980491929 hasPublicationYear "2019" @default.
• W2980491929 type Work @default.
• W2980491929 sameAs 2980491929 @default.
• W2980491929 citedByCount "11" @default.
• W2980491929 countsByYear W29804919292020 @default.
• W2980491929 countsByYear W29804919292021 @default.
• W2980491929 countsByYear W29804919292022 @default.
• W2980491929 crossrefType "journal-article" @default.
• W2980491929 hasAuthorship W2980491929A5007683245 @default.
• W2980491929 hasAuthorship W2980491929A5014416915 @default.
• W2980491929 hasAuthorship W2980491929A5027594065 @default.
• W2980491929 hasAuthorship W2980491929A5028259807 @default.
• W2980491929 hasAuthorship W2980491929A5040735233 @default.
• W2980491929 hasAuthorship W2980491929A5053376791 @default.
• W2980491929 hasAuthorship W2980491929A5068059897 @default.
• W2980491929 hasAuthorship W2980491929A5075849177 @default.
• W2980491929 hasBestOaLocation W29804919291 @default.
• W2980491929 hasConcept C121608353 @default.
• W2980491929 hasConcept C126322002 @default.
• W2980491929 hasConcept C143998085 @default.
• W2980491929 hasConcept C203092338 @default.
• W2980491929 hasConcept C2777863537 @default.
• W2980491929 hasConcept C2779786085 @default.
• W2980491929 hasConcept C2908647359 @default.
• W2980491929 hasConcept C530470458 @default.
• W2980491929 hasConcept C535046627 @default.
• W2980491929 hasConcept C59491497 @default.
• W2980491929 hasConcept C71924100 @default.
• W2980491929 hasConcept C98274493 @default.
• W2980491929 hasConcept C99454951 @default.
• W2980491929 hasConceptScore W2980491929C121608353 @default.
• W2980491929 hasConceptScore W2980491929C126322002 @default.
• W2980491929 hasConceptScore W2980491929C143998085 @default.
• W2980491929 hasConceptScore W2980491929C203092338 @default.
• W2980491929 hasConceptScore W2980491929C2777863537 @default.
• W2980491929 hasConceptScore W2980491929C2779786085 @default.
• W2980491929 hasConceptScore W2980491929C2908647359 @default.
• W2980491929 hasConceptScore W2980491929C530470458 @default.
• W2980491929 hasConceptScore W2980491929C535046627 @default.
• W2980491929 hasConceptScore W2980491929C59491497 @default.
• W2980491929 hasConceptScore W2980491929C71924100 @default.
• W2980491929 hasConceptScore W2980491929C98274493 @default.
• W2980491929 hasConceptScore W2980491929C99454951 @default.
• W2980491929 hasFunder F4320307105 @default.
• W2980491929 hasIssue "6" @default.
• W2980491929 hasLocation W29804919291 @default.
• W2980491929 hasLocation W29804919292 @default.
• W2980491929 hasLocation W29804919293 @default.
• W2980491929 hasLocation W29804919294 @default.
• W2980491929 hasOpenAccess W2980491929 @default.
• W2980491929 hasPrimaryLocation W29804919291 @default.
• W2980491929 hasRelatedWork W2066747782 @default.
• W2980491929 hasRelatedWork W2477982768 @default.
• W2980491929 hasRelatedWork W2761356983 @default.
• W2980491929 hasRelatedWork W2794755138 @default.
• W2980491929 hasRelatedWork W2934222321 @default.

• next